Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour lysis syndrome (TLS) monitoring during venetoclax ramp-up in 170 patients with chronic lymphocytic leukaemia. The primary outcome was clinical/biochemical TLS. Two clinical and four biochemical TLS occurred (4.1%). Five of the six events occurred in high-risk patients, four occurred at 20 mg dose and three at the 6-h time-point. Inpatient versus outpatient TLS rates within the high-risk subgroup were 15% and 8%. Risk category was the only predictor of TLS events in multivariate analysis. Outpatient escalation did not associate with clinically meaningful TLS events, suggesting outpatient escalation has manageable associated TLS risks, including in high-risk cohorts. These observations require confirmation in larger studies.

Original publication

DOI

10.1111/bjh.18738

Type

Journal article

Journal

Br J Haematol

Publication Date

07/2023

Volume

202

Pages

48 - 53

Keywords

Venetoclax, chronic lymphocytic leukaemia, dose ramp-up, tumour lysis syndrome, Humans, Antineoplastic Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Retrospective Studies, Tumor Lysis Syndrome, Bridged Bicyclo Compounds, Heterocyclic